Shares of Biotechnology company Qiagen climbed 1.1% this morning. Here are some quick facts to get you started if you are interested in the stock:
-
Qiagen has logged a 3.0% 52 week change, compared to 12.4% for the S&P 500
-
QGEN has an average analyst rating of buy and is -9.85% away from its mean target price of $49.2 per share
-
Its trailing earnings per share (EPS) is $0.43, which brings its trailing Price to Earnings (P/E) ratio to 103.1. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $2.29 and its forward P/E ratio is 19.4
-
The company has a Price to Book (P/B) ratio of 2.82 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 3.6, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
QGEN has reported YOY quarterly earnings growth of 10.7% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $506.38 Million and the average free cash flow growth rate is 13.5%
-
Qiagen's revenues have an average growth rate of 3.1% with operating expenses growing at -1.5%. The company's current operating margins stand at 4.9%